These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 12728632)

  • 21. [Pefloxacin in the treatment of the bone and joint infections].
    Maiello A; Dassio G; Calvo MM; Gramoni A
    Minerva Med; 1999; 90(1-2):33-7. PubMed ID: 10388461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy of pefoxacin (abactal) in the complex treatment of patients with pancreonecrosis].
    Gel'fand BR; Burnevich SZ; Gel'fand EB; Tsydenzhapov ETs; Briukhov AN; Brazhnik TB; Saganov VP; Pukhaev DA
    Antibiot Khimioter; 2001; 46(5):24-7. PubMed ID: 11558450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of pefloxacin in human prostatic tissue.
    Salpigides G; Pangalis A; Kouvelas D; Paradelis AG
    J Chemother; 1995 Nov; 7 Suppl 4():105-6. PubMed ID: 8904124
    [No Abstract]   [Full Text] [Related]  

  • 24. [The effect of pharmacodynamic parameters of pefloxacin on elastase and protease activity in Pseudomonas aeruginosa].
    Hostacká A
    Epidemiol Mikrobiol Imunol; 1996 Sep; 45(3):119-22. PubMed ID: 8998604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy of the new quinolones in lower respiratory infections.
    Davies BI; Maesen FP
    Chemioterapia; 1987 Jun; 6(2 Suppl):447-8. PubMed ID: 3509469
    [No Abstract]   [Full Text] [Related]  

  • 26. Pefloxacin versus cefuroxime axetil for single-dose therapy of acute uncomplicated lower urinary tract infections in women.
    Krcmery S; Hromec J; Gulla D
    J Chemother; 1995 Nov; 7 Suppl 4():168-9. PubMed ID: 8904145
    [No Abstract]   [Full Text] [Related]  

  • 27. [Effectiveness of pefloxacin in the surgical clinic].
    Iakovlev VP; Blatun LA; Khlebnikov EP; Elagina LV; Puchkova LS
    Antibiot Khimioter; 1995 Aug; 40(8):43-5. PubMed ID: 8713438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparative efficacy and safety of ciprofloxacin, ofloxacin, and pefloxacin in treatment of respiratory infections in children with cystic fibrosis].
    Postnikov SS
    Antibiot Khimioter; 2001; 46(3):16-20. PubMed ID: 11548276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pefloxacin in the treatment of patients with mucoviscidosis].
    Postnikov SS; Semykin SIu; Polikarpova SV; Nazhimov VP
    Antibiot Khimioter; 2002; 47(4):13-5. PubMed ID: 12369138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pefloxacin clinical pharmacokinetics.
    Bressolle F; Gonçalves F; Gouby A; Galtier M
    Clin Pharmacokinet; 1994 Dec; 27(6):418-46. PubMed ID: 7882634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of pefloxacin activity against recent clinical isolates.
    Lembo M; Covelli B; Nani E; Lavitola A
    J Chemother; 1991 Jan; 3 Suppl 1():51-3. PubMed ID: 12041785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of subinhibitory concentrations of pefloxacin in infection in mice due to susceptible or resistant strains.
    Carsenti-Etesse H; Bensoussan M; Bensoussan F; Durant J; Pradier C; Mondain V; Bernard E; Dellamonica P
    Drugs; 1995; 49 Suppl 2():276-8. PubMed ID: 8549331
    [No Abstract]   [Full Text] [Related]  

  • 33. Evaluation of the efficacy of sequential intravenous-oral administration of pefloxacin in community-acquired lower respiratory tract infections in patients with underlying conditions.
    Yap JC; Wang YT; Chan CC; Ng A; Poh SC
    Singapore Med J; 1995 Oct; 36(5):484-6. PubMed ID: 8882529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Chemotherapy activity and pharmacokinetics of the fluoroquinolones generics Ofloxacin-PhPO and Pefloxacin-genova].
    Ptitsina SN; Bobrov VI; Borisov MM
    Antibiot Khimioter; 2007; 52(6):13-6. PubMed ID: 18476469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute gout in a patient taking pefloxacin--a case report.
    Kundu AK
    J Indian Med Assoc; 1996 Nov; 94(11):427. PubMed ID: 9141871
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparative efficacies of oral pefloxacin in uncomplicated cystitis. Single dose or 3-day therapy.
    Leelarasamee A; Leelarasamee I
    Drugs; 1995; 49 Suppl 2():365-7. PubMed ID: 8549364
    [No Abstract]   [Full Text] [Related]  

  • 37. [Evaluation of tolerance and efficacy of pefloxacin in the treatment and prevention of severe infections in children with mucoviscidosis and aplastic anemia].
    Postnikov SS; Semykin SIu; Kapranov NI; Perederko LV; Polikarpova SV; Khamidullina KF
    Antibiot Khimioter; 2000; 45(8):25-30. PubMed ID: 10989721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of pefloxacin on immune response].
    Artsimovich NG; Nastoiashchaia NN; Navashin PS
    Antibiot Khimioter; 2001; 46(4):11-2. PubMed ID: 11550499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Use of pefloxacin in the treatment of patients with purulent wounds of soft tissues].
    Blatun LA; Puchkova LS; Navashin PS; Iakovlev VP; Svetykhin AM
    Antibiot Khimioter; 1999; 44(1):20-2. PubMed ID: 10095920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carrier-mediated system for pefloxacin uptake in human monocytes.
    Mémin E; Panteix G; Revol A
    J Antimicrob Chemother; 1997 Aug; 40(2):263-8. PubMed ID: 9301993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.